[Clinical application of vitamin K for hepatocellular carcinoma].
Despite recent progress in diagnosis and therapy, hepatocellular carcinoma (HCC) remains among the cancers with the poorest prognoses. Vitamin K (VK) have been shown to suppress the growth of HCC cells. Long-term administration of VK(2) has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK against HCC, co-administration of VK(2) with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.
Mizuta
Toshihiko
T
Saga Medical School, Department of Internal Medicine.
Ozaki
Iwata
I
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D002455:Cell Division / Q000187:drug effects; D015195:Drug Design; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D024482:Vitamin K 2 / Q000494:pharmacology / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D024482:Vitamin K 2